CSF3 and infection: In the ECHELON-1 phase III trial, BV–AVD was associated with a higher incidence of febrile neutropenia and infection compared to ABVD, and primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) is now recommended for all patients receiving this regimen.